Treating iCCA With Chemo Pump Can Be as Effective as Surgery, JAMA Study Finds

May 11th 2022, 3:00pm


Cholangiocarcinoma (CCA), or bile duct cancer, is classified by its location, with intrahepatic CCA (iCCA) referring to those cancers that form in bile ducts within the liver.

Improving Diversity in Clinical Trials: How Early-Stage Investigators Are Reaching Underserved Populations

April 13th 2022, 9:42pm


Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.

Preclinical Data at AACR Show CSP May Be Broad Target in Cholangiocarcinoma

April 13th 2022, 12:57pm


Researchers presented results for ZB131, a monoclonal antibody that would target cancer-specific plectin (CSP); experiments with mice showed this may be present in more than 80% of the most common types of cholangiocarcinoma.

Dr Jorge Plutzky Explains How Traditional CV Risk Prediction Models Fall Short for Patients With HIV

March 30th 2022, 5:00pm


Traditional cardiovascular (CV) risk prediction models may not apply accurately to patients with HIV who may develop the cardiovascular disease younger than usual, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.

BITCOIN: FGFR2/3 Alterations Linked to Better Survival in Cholangiocarcinoma

March 26th 2022, 3:27pm


The study by the Veneto Institute of Oncology (IOV) in Padua, Italy, examined 286 patients for genomic mutations in cholangiocarcinoma as well as survival status.

Dr Shoaib Ugradar Discusses Teprotumumab for Thyroid Eye Disease and Data Collected

March 21st 2022, 1:00pm


Teprotumumab has shown great efficacy in treating thyroid eye disease in both clinical trials and real-world settings, but more data are needed on adverse events, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.

Study Identifies Markers for Presurgical Staging System in Cholangiocarcinoma

March 12th 2022, 8:08pm


A study from Japan identifies markers for a presurgical staging system in intrahepatic cholangiocarcinoma, with results on par with an existing postsurgical staging system.

Dr Robert Fante: More Data Will Provide More Insight Into Use of Teprotumumab for TED

March 7th 2022, 8:13pm


As more data are gathered on teprotumumab for use in thyroid eye disease (TED), we’ll have a better understanding of which subgroups respond better or worse to the treatment, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Study Links Certain Cancers With Increased Risk of Guillain-Barré Syndrome

March 3rd 2022, 10:30pm


Not all Guillain-Barré cases are associated with infection, and studies have suggested a link between the rare disorder and certain cancers, including lymphomas.

With Natural Killer Cell Immunotherapy, Alloreactive Cell Dose May Be Predictive of Response

February 26th 2022, 4:00pm


Research has shown that adoptive immunotherapy using natural killer cells may be beneficial in leukemia treatment. The follow-up to a recent study found that the dose of alloreactive natural killer cells matters for treatment response.